Can I Take Vitamin B6 with Enclomiphene Citrate?

Vitamin B6 (pyridoxine, or its active coenzyme form pyridoxal-5-phosphate) has no documented pharmacokinetic interaction with enclomiphene citrate, an oral selective estrogen receptor modulator (SERM) prescribed off-label for men with secondary hypogonadism. At dietary or low supplemental doses, up to the NIH tolerable upper intake level of 100 mg/day, combining the two is considered low-risk based on the mechanisms reviewed below. The relevant safety issue is not an interaction between the two compounds; it is B6's own dose-dependent risk of peripheral sensory neuropathy at sustained high doses, a risk that exists whether or not a person is also taking enclomiphene.

What enclomiphene citrate is, and what it is not

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It blocks estrogen negative feedback at the hypothalamus and pituitary, which raises endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and, in turn, raises testosterone produced by the testes rather than replacing it exogenously. This is the main reason it is prescribed instead of testosterone replacement in men who want to preserve fertility.

A branded formulation (Androxal) went through Phase III trials but was not granted final FDA approval. Enclomiphene is currently available to patients through compounding pharmacies as an off-label prescription, not as an FDA-approved drug in its own right. The FDA-approved label referenced in this article is for clomiphene citrate (Clomid), the racemic mixture that contains both the trans (enclomiphene) and cis (zuclomiphene) isomers; enclomiphene-specific labeling does not exist because the standalone product was never approved. FDA clomiphene citrate label

The 2018 Endocrine Society clinical practice guideline on male hypogonadism discusses SERMs, including clomiphene, as an option that can raise testosterone in men with secondary hypogonadism who wish to preserve fertility, but it does not issue an enclomiphene-specific recommendation and does not address supplement co-administration. Endocrine Society guideline, PubMed

Clomiphene isomers are metabolized mainly by hepatic CYP3A4 with additional involvement of other CYP enzymes. CYP450 background, PubMed Enclomiphene's own half-life is much shorter than that of zuclomiphene, which matters mainly for how long any theoretical metabolic overlap with a co-administered substance would persist, not because a specific B6 interaction has been demonstrated.

What vitamin B6 does, and where the dose lines are

Vitamin B6 is a water-soluble vitamin whose active coenzyme form, pyridoxal-5-phosphate (PLP), participates in amino acid metabolism and neurotransmitter synthesis, including dopamine, serotonin, and GABA. Vitamin B6 review, PubMed

The NIH Office of Dietary Supplements lists the adult RDA at roughly 1.3 to 1.7 mg/day and sets a tolerable upper intake level (UL) of 100 mg/day for adults from supplements and food combined. NIH Vitamin B6 fact sheet Multivitamins typically supply 2 to 10 mg; standalone B6 tablets commonly range from 25 mg to 500 mg, which means it is easy to exceed the UL without realizing it, especially when B-complex, multivitamin, and standalone products are stacked.

Sustained pyridoxine intake above roughly 200 mg/day has been associated with sensory peripheral neuropathy since it was first described in a 1983 case series. Schaumburg et al., PubMed Later reviews describe neuropathy occurring at lower chronic doses in some individuals, though most reported cases involve doses well above the NIH UL. B-vitamin neurologic review, PubMed A separate 2023 EFSA scientific opinion revisited the tolerable intake question and proposed a more conservative supplemental limit than the NIH figure; the exact number and its applicability to a US clinical audience should be verified against the primary EFSA opinion before it is used to counsel a specific patient. EFSA vitamin B6 opinion, PubMed

Is there a pharmacokinetic interaction?

No published study has directly tested B6 and enclomiphene together. Based on known metabolic pathways, a clinically meaningful pharmacokinetic interaction is unlikely at standard supplemental doses, but "unlikely based on mechanism" is not the same as "studied and ruled out."

CYP enzymes. Enclomiphene is metabolized in part by CYP3A4. Vitamin B6 is not established as a clinically significant CYP3A4 inhibitor or inducer in standard pharmacology references. General CYP450 background supports this reasoning, though no source specifically tested B6 against enclomiphene exposure, so this point rests on mechanistic plausibility rather than a direct interaction study. CYP450 background, PubMed Strong CYP3A4 inhibitors that do have documented relevance to clomiphene-class compounds include azole antifungals and certain other prescription drugs; that risk is unrelated to B6 and is far more clinically significant. FDA clomiphene citrate label

Transport proteins. Clomiphene isomers show some affinity for P-glycoprotein efflux transport, a general property of many ABC-family transporter substrates. Transporter background, PubMed There is no specific evidence that standard-dose B6 meaningfully affects this transporter; this is again a plausibility argument, not a tested finding.

Protein binding. Enclomiphene binds plasma proteins including albumin and sex hormone-binding globulin; PLP also binds albumin. Displacement interactions generally require molar concentrations far above typical dosing, which makes clinically relevant displacement improbable at 25 mg/day enclomiphene and 100 mg/day B6, though this has not been directly measured for this pair.

The risk that actually matters: B6 toxicity, not B6-enclomiphene interaction

The practical hazard is not a drug-supplement interaction in the classic sense. It is that high-dose B6 neuropathy and enclomiphene's own known side effects can look alike, which complicates figuring out what is causing a new symptom.

Enclomiphene, like other SERMs, can cause visual disturbances in a minority of users. High-dose B6 causes sensory symptoms: numbness, tingling, and balance problems that develop over weeks to months. If someone takes both and develops a sensory or visual complaint, distinguishing the cause requires a careful history and possibly a lab test, not guesswork. Keeping B6 at or below the NIH UL of 100 mg/day removes most of that diagnostic ambiguity.

There is no evidence that enclomiphene's mechanism depends on B6 status, and no evidence that standard-dose B6 blunts or amplifies the SERM-driven LH increase. Severe B6 deficiency could theoretically impair steroidogenic enzyme function, since some of those reactions are PLP-dependent, but frank deficiency is uncommon in men eating a mixed diet, and there is no evidence that supplementing above sufficiency accelerates testosterone synthesis beyond what LH stimulation already produces.

A separate, smaller body of older research suggests B6 at doses of roughly 200 mg/day or higher may modestly lower prolactin through its role in dopamine synthesis. Shaarawy et al., PubMed Enclomiphene does not directly lower prolactin. Whether combining the two produces a meaningful additive effect on prolactin has not been studied, which is a reasonable argument for checking a baseline prolactin level before starting either agent rather than assuming the combination is neutral.

Evidence-status interaction assessment

What the enclomiphene efficacy trials actually show

Two industry-associated trials are commonly cited for enclomiphene's hormonal effects in secondary hypogonadism: a randomized trial by Kim and colleagues comparing enclomiphene with topical testosterone, and a dose-finding study by Wiehle and colleagues. Kim et al., BJU International, PubMed Wiehle et al., BJU International, PubMed Both reported meaningful testosterone increases with enclomiphene while preserving sperm parameters, in contrast to testosterone declines typically seen with exogenous gel. Readers who want the exact magnitude of testosterone change reported in these trials should consult the papers directly rather than relying on any single restated figure, since precise numbers are easy to misquote across secondary sources.

Neither trial evaluated vitamin B6 or any other supplement alongside enclomiphene. The absence of a combined trial does not mean the combination is unsafe; it means the specific question asked in this article has not been formally tested, and the answer here is built from separate literatures on enclomiphene pharmacology and B6 toxicity, not from a study of the two together.

Dose guidance

Dietary and multivitamin levels (roughly 2 to 10 mg/day). No known concern. This range has no plausible interaction with enclomiphene and is far below any neuropathy threshold. NIH Vitamin B6 fact sheet

Low supplemental doses (10 to 100 mg/day). Generally acceptable for most adults and within the NIH UL. No pharmacokinetic interaction with enclomiphene is expected at this range.

Higher supplemental doses (100 to 200 mg/day). Exceeds the NIH UL. Some people tolerate this without symptoms, but the margin of safety narrows. Discuss continued use at this level with the prescribing clinician, particularly for long-term use.

Very high doses (above 200 mg/day). Avoid without direct medical supervision. This range is where peripheral neuropathy has been most consistently reported, with onset sometimes taking weeks to months. There is no established benefit from doses this high in the context of enclomiphene treatment.

Monitoring: what to check and what to ask about

Baseline labs before starting enclomiphene typically include total testosterone, LH, FSH, estradiol, and prolactin, along with a general metabolic panel, as part of routine off-label hypogonadism workup. If B6 supplementation above roughly 50 mg/day is planned or already in use, a baseline note of sensory function is reasonable, particularly for patients over 50 or with diabetes, since diabetic neuropathy can be mistaken for B6 toxicity or vice versa.

At follow-up visits, ask specifically about:

• Numbness, tingling, or burning in the hands or feet (possible high-dose B6 effect)
• New visual changes (a recognized SERM class effect that needs its own evaluation)
• Mood or sleep changes (both enclomiphene and high-dose B6 can affect neurotransmitter tone, though evidence for B6 improving mood in this context is anecdotal rather than trial-based)

A serum pyridoxal-5-phosphate level can help confirm B6 status if neuropathy symptoms appear; a level clearly above the normal range in a symptomatic patient supports reducing B6 intake as a first step, in coordination with the prescriber. Cumulative B6 intake should be tallied across every source: multivitamin, B-complex, standalone tablets, and fortified protein powders, since these commonly stack without the patient noticing.

Interactions between enclomiphene and strong CYP3A4-affecting prescription drugs (certain azole antifungals, some antibiotics, rifampin) are more clinically significant than anything related to B6 and should be reviewed with the prescribing clinician before starting enclomiphene, independent of any supplement question. FDA clomiphene citrate label

What is established, what is plausible, and what is not known

Established: enclomiphene raises LH and testosterone through estrogen-receptor blockade at the hypothalamic-pituitary axis; it is not FDA-approved as a standalone drug and is used off-label; B6 has a well-described dose-dependent neuropathy risk at high chronic intake; the NIH UL for B6 is 100 mg/day.

Plausible but unproven: that B6 at 200 mg/day or higher modestly lowers prolactin in a way that is additive with enclomiphene's hormonal effects; that PLP-form B6 carries a somewhat lower neuropathy risk than pyridoxine at equivalent doses.

Not established: any pharmacokinetic interaction between B6 and enclomiphene at any dose; any effect of B6 supplementation on enclomiphene's efficacy, on estradiol, or on SHBG in men undergoing this treatment; any benefit of B6 supplementation specific to men on enclomiphene therapy.

Practical steps

For patients. Check the B6 dose on your supplement label. At 100 mg or below, no special timing or separation from enclomiphene is needed; take each on whatever schedule fits your routine. If your supplement exceeds 100 mg per dose, or if you are combining multiple B6-containing products, talk to your prescriber before continuing at that level. Report any new numbness, tingling, or balance problems at your next visit regardless of which supplement you suspect, since your prescriber needs the full picture to sort out the cause. Avoid megadose B6 (500 mg or higher) during enclomiphene therapy; there is no documented benefit at that dose in this context and a real, described neuropathy risk.

For prescribers. Review the complete supplement list, not just prescription medications, at every enclomiphene follow-up visit. Off-label SERM users frequently self-add multiple supplements at once. Cumulative B6 above 200 mg/day from all sources combined warrants counseling regardless of the source product. If a patient reports new sensory symptoms, consider a serum PLP level and a tally of total B6 intake across every product before attributing the symptom to enclomiphene itself.